Chipscreen Biosciences and its wholly-owned subsidiary, Shenzhen Chipscreen Pharmaceutical, have recently received the "Notice of Acceptance" issued by the Center for Drug Evaluation of the National Medical Products Administration. The clinical trial application for the company's self-developed CS231295 tablets, intended for combination therapy in glioblastoma, has been accepted for review. This drug is a novel, highly selective multi-target protein kinase inhibitor targeting Aurora B, with good blood-brain barrier permeability. Phase I data demonstrated preliminary antitumor activity in patients with recurrent or progressive glioblastoma. This is a new drug clinical trial application. If no negative or objectionable opinions are received within 60 days from the date of acceptance, the clinical trial may proceed according to the protocol; however, whether it will ultimately be conducted remains uncertain.